348 related articles for article (PubMed ID: 19012178)
21. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues.
Matthews JS; Jones RL
Br J Pharmacol; 1993 Feb; 108(2):363-9. PubMed ID: 8448586
[TBL] [Abstract][Full Text] [Related]
22. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
23. Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin.
Fox SC; May JA; Shah A; Neubert U; Heptinstall S
Platelets; 2009 Jun; 20(4):250-9. PubMed ID: 19440925
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
Behan MW; Fox SC; Heptinstall S; Storey RF
Platelets; 2005 Mar; 16(2):73-80. PubMed ID: 15823862
[TBL] [Abstract][Full Text] [Related]
25. Prostaglandin E potentiates the immunologically stimulated histamine release from human peripheral blood-derived mast cells through EP1/EP3 receptors.
Wang XS; Lau HY
Allergy; 2006 Apr; 61(4):503-6. PubMed ID: 16512814
[TBL] [Abstract][Full Text] [Related]
26. Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
Kobsar AL; Koessler J; Rajkovic MS; Brunner KP; Steigerwald U; Walter U
Platelets; 2010; 21(2):112-6. PubMed ID: 20085435
[TBL] [Abstract][Full Text] [Related]
27. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model.
Huang J; Driscoll EM; Gonzales ML; Park AM; Lucchesi BR
J Pharmacol Exp Ther; 2000 Nov; 295(2):492-9. PubMed ID: 11046080
[TBL] [Abstract][Full Text] [Related]
28. The EP3-agonist sulprostone, but not prostaglandin E2 potentiates platelet aggregation in human blood.
Schober LJ; Khandoga AL; Penz SM; Siess W
Thromb Haemost; 2010 Jun; 103(6):1268-9. PubMed ID: 20431854
[No Abstract] [Full Text] [Related]
29. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
Frelinger AL; Jakubowski JA; Li Y; Barnard MR; Fox ML; Linden MD; Sugidachi A; Winters KJ; Furman MI; Michelson AD
Thromb Haemost; 2007 Jul; 98(1):192-200. PubMed ID: 17598013
[TBL] [Abstract][Full Text] [Related]
30. Anti-inflammatory effect of prostanoids in mouse and rat skin: evidence for a role of EP3-receptors.
Ahluwalia A; Perretti M
J Pharmacol Exp Ther; 1994 Mar; 268(3):1526-31. PubMed ID: 8138964
[TBL] [Abstract][Full Text] [Related]
31. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.
Storey RF; Sanderson HM; White AE; May JA; Cameron KE; Heptinstall S
Br J Haematol; 2000 Sep; 110(4):925-34. PubMed ID: 11054084
[TBL] [Abstract][Full Text] [Related]
32. Cangrelor attenuates coated-platelet formation.
Norgard NB; Hann CL; Dale GL
Clin Appl Thromb Hemost; 2009; 15(2):177-82. PubMed ID: 18796456
[TBL] [Abstract][Full Text] [Related]
33. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy.
Rozalski M; Nocun M; Watala C
Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207
[TBL] [Abstract][Full Text] [Related]
34. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.
Zhao L; Bath P; Heptinstall S
Br J Pharmacol; 2001 Sep; 134(2):353-8. PubMed ID: 11564653
[TBL] [Abstract][Full Text] [Related]
35. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
[TBL] [Abstract][Full Text] [Related]
36. Modulation of platelet and leucocyte function by a Chinese herbal formulation as compared with conventional antiplatelet agents.
Zhao L; Gaudry L; Dunkley S; Brighton T; Guo ZX; Ye ZL; Luo RZ; Chesterman CN
Platelets; 2008 Feb; 19(1):24-31. PubMed ID: 18231935
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets.
Harmon S; Inkielewicz-Stepniak I; Jones M; Ledwidge M; Santos-Martinez MJ; Medina C; Radomski MW; Gilmer JF
J Pharm Pharmacol; 2012 Jan; 64(1):77-89. PubMed ID: 22150675
[TBL] [Abstract][Full Text] [Related]
38. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
[TBL] [Abstract][Full Text] [Related]
39. Modulation of bladder function by prostaglandin EP3 receptors in the central nervous system.
Su X; Leon LA; Wu CW; Morrow DM; Jaworski JP; Hieble JP; Lashinger ES; Jin J; Edwards RM; Laping NJ
Am J Physiol Renal Physiol; 2008 Oct; 295(4):F984-94. PubMed ID: 18632791
[TBL] [Abstract][Full Text] [Related]
40. The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood.
Schober LJ; Khandoga AL; Dwivedi S; Penz SM; Maruyama T; Brandl R; Siess W
J Thromb Thrombolysis; 2011 Aug; 32(2):158-66. PubMed ID: 21424266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
